Last reviewed · How we verify

IV PCA Fentanyl+nefopam+Ramosetron

Keimyung University Dongsan Medical Center · Phase 3 active Small molecule

This IV patient-controlled analgesia (PCA) combination provides opioid analgesia via fentanyl, reduces postoperative nausea and vomiting via ramosetron (5-HT3 antagonist), and enhances analgesia while reducing opioid requirements via nefopam (non-opioid analgesic).

This IV patient-controlled analgesia (PCA) combination provides opioid analgesia via fentanyl, reduces postoperative nausea and vomiting via ramosetron (5-HT3 antagonist), and enhances analgesia while reducing opioid requirements via nefopam (non-opioid analgesic). Used for Postoperative pain management via intravenous patient-controlled analgesia.

At a glance

Generic nameIV PCA Fentanyl+nefopam+Ramosetron
Also known asintravenous patient-controlled analgesia
SponsorKeimyung University Dongsan Medical Center
Drug classOpioid analgesic combination with antiemetic and adjuvant analgesic
TargetMu-opioid receptor (fentanyl); 5-HT3 receptor (ramosetron); monoamine transporters and NMDA receptor (nefopam)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhasePhase 3

Mechanism of action

Fentanyl is a potent mu-opioid receptor agonist that provides the primary analgesic effect. Ramosetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone neurons to prevent nausea and vomiting. Nefopam is a non-opioid analgesic that works through monoamine reuptake inhibition and NMDA receptor antagonism, reducing total opioid consumption and improving pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: